Stryker (NYSE:SYK) Insider Dylan Bram Crotty Sells 441 Shares of Stock

Stryker Corporation (NYSE:SYK) insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Stryker Stock Down 0.2%

Shares of NYSE:SYK traded down $0.51 on Wednesday, reaching $330.08. The company had a trading volume of 1,571,356 shares, compared to its average volume of 2,364,547. The firm has a market capitalization of $126.61 billion, a PE ratio of 34.21, a PEG ratio of 2.09 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm’s 50 day simple moving average is $327.80 and its 200-day simple moving average is $331.95. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Hedge Funds Weigh In On Stryker

A number of institutional investors have recently modified their holdings of SYK. California State Teachers Retirement System raised its position in Stryker by 30,523.4% during the second quarter. California State Teachers Retirement System now owns 163,395,348 shares of the medical technology company’s stock valued at $51,443,391,000 after acquiring an additional 162,861,784 shares in the last quarter. State Street Corp boosted its position in Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares during the period. Geode Capital Management LLC increased its holdings in shares of Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Stryker during the 4th quarter valued at approximately $1,822,272,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on SYK. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Barclays decreased their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. JPMorgan Chase & Co. cut their price target on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.